The short version of nitric oxide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Denturist curriculum contains courses such as, General biology, Microbiology, Human anatomy, Head and Neck anatomy, Dental anatomy, Physiology, Dental Materials, Dental technology theory, Infection prevention and control, Radiographic interpretation, Periodontology, Histology, Embryology, Nutrition, Psychology, Pathophysiology, Oral pathology, Pharmacology, Gerontology, Ethics, Removable and Fixed prosthetics, Implantology, Removable oral appliances, Clinical & Laboratory theory, Practice management, etc. The program is competitive and selective. Completing a Dental Technology Degree prior to entering Denture Specialist Program is a common academic path. By acquiring Dental Technology knowledge prior to entering Denture Specialist Program provides foundational knowledge for the advanced curriculum. Work experience from denturist clinic or denture laboratory is considered advantageous for program completion and career progression.
=== ZonaZoo === Officially implemented in 2003, ZonaZoo is the official student section and student ticketing program for the University of Arizona Athletics. The ZonaZoo program is co-owned by the Associated Students of the University of Arizona (ASUA) and Arizona Athletics yet run by a team of individuals called the ZonaZoo Crew. In 2014, ESPN ranked ZonaZoo as the top student cheering section in the PAC 12 conference and in 2015, and in 2018, ZonaZoo received the Best Student Section of the Year award from the National Collegiate Student Section Association.
== Properties == The alcohol dehydrogenases comprise a group of several isozymes that catalyse the oxidation of primary and secondary alcohols to aldehydes and ketones, respectively, and also can catalyse the reverse reaction. In mammals this is a redox (reduction/oxidation) reaction involving the coenzyme nicotinamide adenine dinucleotide (NAD+).
=== 1970s === 1975: Chien-Shiung Wu, born in China but having become an American citizen in 1954, became the first female president of the American Physical Society. 1976: Margaret Burbidge, born in England, was named as the first female president of the American Astronomical Society. 1977: Rosalyn Yalow received the Nobel Prize in Physiology or Medicine "for the development of radioimmunoassays of peptide hormones"; she shared it with Roger Guillemin and Andrew V. Schally "for their discoveries concerning the peptide hormone production of the brain." 1978: Anna Jane Harrison became the first female president of the American Chemical Society. 1978: Mildred Cohn served as the first female president of the American Society for Biochemistry and Molecular Biology, then called the American Society of Biological Chemists.
{\displaystyle \mathrm {Purity} ={\frac {w_{\mathrm {std} }\times n[\mathrm {H} ]_{\mathrm {std} }\times MW_{\mathrm {spl} }}{w_{\mathrm {spl} }\times MW_{\mathrm {std} }\times n[\mathrm {H} ]_{\mathrm {spl} }}}\times P}
Sources: en.wikipedia.org
== Regulation of gonadotropic cells == Gonadotroph release of gonadotropins is highly regulated and fluctuates with physiological conditions. For example, in the presence of gonadotropins, ovaries produce and secrete the hormone estradiol. Increased levels of estradiol regulate the surge in LH levels through a negative feedback mechanism during the mid-cycle of the menstrual cycle. This indicates that LH released from gonadotrophs stimulates the production of estradiol; however, when there is a drastic increase in estradiol production, estradiol will regulate LH production by preventing gonadotrophs from releasing more LH until estradiol is needed again. In males, LH stimulates the production of testosterone by Leydig cells in testis and FSH controls spermatogenesis. Testosterone will also provide negative feedback to gonadotrophs and regulate its own production by acting on the hypothalamus and anterior pituitary. The negative feedback provided by these sex steroids (estradiol and testosterone) lead to the inhibition of hypothalamic secretion of GnRH, which consequently will inhibit the release of LH from gonadotropic cells. FSH is selectively inhibited by paracrine factors, such as inhibin. Inhibin A is secreted from ovarian granulosa cells in females, and inhibin B is secreted by testicular Sertoli cells in males. Similar to the negative feedback of the sex steroids, the inhibin will provide feedback to the pituitary gonadotrophs to reduce secretion of FSH by inhibiting GnRH from activating the release of gonadotropins.
In all cases where β+ decay (positron emission) of a nucleus is allowed energetically, so too is electron capture allowed. This is a process during which a nucleus captures one of its atomic electrons, resulting in the emission of a neutrino:
=== Thrombolysis, stenting and surgery === Thrombolysis, stenting and surgery are not used as widely as anticoagulation or antiplatelet drugs. These treatments are invasive, and are typically reserved for situations where symptoms worsen despite medical treatment, or where medical treatment may be unsafe (e.g. an unacceptable bleeding tendency). Thrombolysis is enzymatic destruction of blood clots. This is achieved by the administration of a drug (such as urokinase or alteplase) that activates plasmin, an enzyme that occurs naturally in the body and digests clots when activated. Thrombolysis is an accepted treatment for heart attacks and stroke unrelated to dissection. In cervical artery dissection, only small case series are available. The thrombolytic drug is administered either intravenously or during cerebral angiography through a catheter directly into the affected artery. The data indicates that thrombolysis is safe, but its place in the treatment of VAD is uncertain. Stenting involves the catheterization of the affected artery during angiography, and the insertion of a mesh-like tube; this is known as "endovascular therapy" (inside the blood vessel). This may be performed to allow the blood to flow through a severely narrowed vessel, or to seal off an aneurysm. However, it is unclear whether the technical success of the procedure translates into improved outcomes, as in both cases the problem often resolves spontaneously over time.
== Properties == Protolichesterinic acid is a member of the class of chemicals known as lactone fatty acids, a group that includes lichesterinic acid, alloprotolichesterinic acid, nephromopsinic acid, and nephrosterinic acid. In its purified form, protolichesterinic acid is a crystalline solid that forms lustrous plates when recrystallized from benzene or acetic acid at temperatures below 50 °C (122 °F). It has a melting point of 107.5 °C (225.5 °F). The compound exists in both enantiomeric forms, with the (+)-enantiomer showing an optical rotation of [α]D +12° in chloroform and the (-)-enantiomer showing [α]D -12° in chloroform. In ultraviolet–visible spectroscopy, it shows maximum absorption at 218 nm in methanol. Its infrared spectrum (KBr) shows characteristic peaks including those corresponding to carboxylic acid (3450 cm−1), alkene (3050 cm−1), and carbonyl (1720 cm−1) functionalities. Nuclear magnetic resonance spectroscopy confirms its structure, with distinctive signals in the 1H NMR spectrum including the terminal methyl group at δ 0.68 ppm and alkene protons at δ 6.03 and 6.39 ppm. The 13C NMR spectrum shows key resonances for the carboxylic acid (174.4 ppm), alkene (132.6 and 125.9 ppm), and lactone carbonyl (168.2 ppm) carbons.
Pharmaceutical drugs that are substituted phenethylamines include phenelzine, phenformin, and fanetizole, among many others. The N-methylated derivative of phenethylamine is N-methylphenethylamine. A deuterated isotopologue of phenethylamine with resistance to monoamine oxidase (MAO)-mediated metabolism is α,α-dideuterophenethylamine. A notable prodrug of phenethylamine with sustained effects is N-(2-cyanoethyl)phenethylamine (CEPEA). Other prodrugs of phenethylamine have been described as well. Analogues of phenethylamine with the ethylamine side chain extended or shortened include phenylpropylamine and benzylamine. Another related analogue is phenylalaninol.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.